Michihiro Satoh1, Taku Obara2,3,4, Hidekazu Nishigori5, Nobuhiro Ooba6, Yoshihiko Morikawa7, Mami Ishikuro8,9, Hirohito Metoki5,10, Masahiro Kikuya8,9, Nariyasu Mano1. 1. Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, 980-8575, Japan. 2. Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, 980-8575, Japan. dontaku@mail.tains.tohoku.ac.jp. 3. Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-cho, Aoba-ku, Sendai, Japan. dontaku@mail.tains.tohoku.ac.jp. 4. Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Japan. dontaku@mail.tains.tohoku.ac.jp. 5. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan. 6. School of Pharmacy, Nihon University, Chiba, Japan. 7. Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan. 8. Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-cho, Aoba-ku, Sendai, Japan. 9. Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Japan. 10. Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Abstract
BACKGROUND: The only drug approved for pervasive developmental disorders (PDD) in Japan is pimozide. Several psychotropic drugs are also prescribed for offlabel use in Japan, but details regarding their prescription and use are largely unknown. The purpose of this study was to clarify the use of drug treatment in Japanese children with PDD. METHODS: Data were extracted from claims data from the Japan Medical Data Center for children younger than 18 years of age who were newly diagnosed with PDD (International Classification of Diseases version 10 codes: F84) from 2005 to 2010 (total of 3276 patients as of 2010). The prescription rates were presented as the percentage of PDD patients who were prescribed each drug. RESULTS: Prior to 2010, the prescription rates for atypical antipsychotics, other antipsychotics, psychostimulants, all other central nervous system drugs, anticovnvulsants, non-barbiturates, and Parkinson's disease/syndrome drugs significantly increased among the Anatomical Therapeutic Chemical classifications defined as the "nervous system" (trend P≤0.02). The prescription rate for risperidone consistently increased, reaching 6.9% in 2010 (trend P<0.0001), the highest rate of the surveyed drugs among the antipsychotics. The prescription rate for aripiprazole also increased (trend P<0.0001), reaching 1.9% in 2010. The prescription rate for pimozide showed no annual changes, with a low rate of 0.4% in 2010. CONCLUSION: Compared with pimozide, the prescription rates for risperidone, aripiprazole and other psychotropic drugs have increased. Because safety data for these drugs in Japanese children are sparse, there is a need for future safety evaluations of these drugs in Japanese children.
BACKGROUND: The only drug approved for pervasive developmental disorders (PDD) in Japan is pimozide. Several psychotropic drugs are also prescribed for offlabel use in Japan, but details regarding their prescription and use are largely unknown. The purpose of this study was to clarify the use of drug treatment in Japanese children with PDD. METHODS: Data were extracted from claims data from the Japan Medical Data Center for children younger than 18 years of age who were newly diagnosed with PDD (International Classification of Diseases version 10 codes: F84) from 2005 to 2010 (total of 3276 patients as of 2010). The prescription rates were presented as the percentage of PDDpatients who were prescribed each drug. RESULTS: Prior to 2010, the prescription rates for atypical antipsychotics, other antipsychotics, psychostimulants, all other central nervous system drugs, anticovnvulsants, non-barbiturates, and Parkinson's disease/syndrome drugs significantly increased among the Anatomical Therapeutic Chemical classifications defined as the "nervous system" (trend P≤0.02). The prescription rate for risperidone consistently increased, reaching 6.9% in 2010 (trend P<0.0001), the highest rate of the surveyed drugs among the antipsychotics. The prescription rate for aripiprazole also increased (trend P<0.0001), reaching 1.9% in 2010. The prescription rate for pimozide showed no annual changes, with a low rate of 0.4% in 2010. CONCLUSION: Compared with pimozide, the prescription rates for risperidone, aripiprazole and other psychotropic drugs have increased. Because safety data for these drugs in Japanese children are sparse, there is a need for future safety evaluations of these drugs in Japanese children.
Authors: Amanda J Baxter; Theo Vos; Kate M Scott; Rosana E Norman; Abraham D Flaxman; Jed Blore; Harvey A Whiteford Journal: Int J Methods Psychiatr Res Date: 2014-07-22 Impact factor: 4.035
Authors: Ovsanna T Leyfer; Susan E Folstein; Susan Bacalman; Naomi O Davis; Elena Dinh; Jubel Morgan; Helen Tager-Flusberg; Janet E Lainhart Journal: J Autism Dev Disord Date: 2006-10